The METTEN study demonstrated that the rate of pathological complete response was higher in women patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab combined with metformin than in patients treated with chemotherapy plus trastuzumab [51]. Here, ERBB2 is linked to breast cancer.